

geron

U.S. UTILITY PATENT APPLICATION

Title INACTIVE VARIANTS OF THE
HUMAN TELOMERASE CATALYTIC SUBUNIT

Inventor Gregg B. Morin
Oakville, Ontario, Canada

**Filing
Information** Date: November 21, 2001
Express Mail No. EF 279208481 US
Docket: 018/258c

Correspondence J. Michael Schiff
Registration No. 40,253

Geron Corporation
230 Constitution Drive
Menlo Park, CA 94025
Phone: (650) 473-7715
Fax: (650) 473-8654

USPTO Customer No. 022869

Priority	This application is a continuation of U.S. Patent Application 09/128,354, filed August 3, 1998, pending; which is a continuation-in-part of U.S. Patent Application 09/052,864, filed March 31, 1998, now abandoned.
-----------------	--

INACTIVE VARIANTS OF THE HUMAN TELOMERASE CATALYTIC SUBUNIT

CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a continuation of U.S. Patent Application 09/128,354, filed August 3, 1998, pending; which is a continuation-in-part of U.S. Patent Application 09/052,864, filed March 31, 1998, now abandoned.

The aforelisted priority applications are hereby incorporated herein by reference in their entirety, as are the following: U.S. Applications 08/851,843; 08/854,050; 08/911,312; 08/912,951; 08/915,503; 08/974,549; and 08/974,584; and International Applications PCT/US97/17618 and PCT/US97/17885, which designate the U.S. and were published on October 1, 1998.

FIELD

The present invention is related to the catalytic protein subunit of human telomerase. The invention provides methods and compositions relating to medicine, molecular biology, chemistry, pharmacology, and medical diagnostic and prognostic technology.

BACKGROUND

The following discussion is intended to introduce the field of the present invention to the reader. The citation of various references in this section should not be construed as an admission of prior invention.

It has long been recognized that complete replication of the ends of eukaryotic chromosomes requires specialized cell components (Watson, 1972, *Nature New Biol.*, 239:197; Olovnikov, 1973, *J. Theor. Biol.*, 41:181). Replication of a linear DNA strand by conventional DNA polymerase requires an RNA primer, and can proceed only 5' to 3'. When the RNA bound at the extreme 5' ends of eukaryotic chromosomal DNA strands is removed, a gap is introduced, leading to a progressive shortening of daughter strands with each round of replication. This shortening of telomeres, the protein-DNA structures physically located on the ends of chromosomes, is thought to account for the phenomenon of cellular senescence or aging of normal human somatic cells *in vitro* and *in vivo*. The maintenance of telomeres is a function of a telomere-specific DNA polymerase known as telomerase. Telomerase is a ribonucleoprotein (RNP) that uses a portion of its RNA moiety as a template for telomeric DNA synthesis (Morin, 1997, *Eur. J. Cancer* 33:750). The length and integrity of telomeres and the telomerase expression status of a cell is thus related to entry of a cell into a senescent stage (*i.e.*, loss of proliferative capacity), or the ability of a cell to escape senescence, *i.e.*, to become immortal.

Consistent with the relationship of telomeres and telomerase to the proliferative capacity of a cell (*i.e.*, the ability of the cell to divide indefinitely), telomerase activity is detected in immortal cell lines and an extraordinarily diverse set of tumor tissues, but is not detected (*i.e.*, was absent or below the assay threshold) in normal somatic cell cultures or normal tissues adjacent to a tumor (see, U.S. Patent Nos. 5,629,154; 5,489,508; 5,648,215; and 5,639,613; see also, Morin, 1989, *Cell* 59: 521; Shay and Bacchetti 1997, *Eur. J. Cancer* 33:787; Kim et al., 1994, *Science* 266:2011; Counter et al., 1992, *EMBO J.* 11:1921; Counter et al., 1994, *Proc. Natl. Acad. Sci. U.S.A.* 91, 2900; Counter et al., 1994, *J. Virol.* 68:3410). Moreover, a correlation between the level of telomerase activity in

a tumor and the likely clinical outcome of the patient has been reported (e.g., U.S. Patent No. 5,639,613, *supra*; Langford et al., 1997, *Hum. Pathol.* 28:416). Thus, human telomerase is an ideal target for diagnosing and treating human diseases relating to cellular proliferation and senescence, such as cancer, or for increasing the proliferative capacity of a cell.

SUMMARY

In one aspect, the invention provides an isolated or recombinant hTERT polypeptide that has telomerase catalytic activity. In one embodiment, the hTERT polypeptide has a deletion of at least 25 residues in the regions corresponding to residues 192-323, 200-323, 192-271, 200-271, 222-240, 415-450, 192-323 and 415-450, or 192-271 and 415-450 of hTERT. In a related embodiment, residues 192-323, 200-323, 192-271, 200-271, 222-240, 415-450, 192-323 and 415-450, or 192-271 and 415-450 of hTERT are deleted. The invention also provides a polynucleotide comprising a nucleotide sequence encoding these hTERT polypeptides. In some embodiments, the polynucleotide includes a promoter sequence operably linked to the nucleotide sequence encoding the hTERT polypeptide.

The invention also provides a method of preparing recombinant telomerase by contacting a recombinant hTERT polypeptide containing a deletion as described *supra* with a telomerase RNA component under conditions such that the recombinant protein and the telomerase RNA component associate to form a telomerase enzyme capable of catalyzing the addition of nucleotides to a telomerase substrate. The hTERT polypeptide may be produced in an *in vitro* expression system and/or may be purified before the contacting step. In some embodiments, the contacting occurs in a cell.

The invention further provides a method for increasing the proliferative capacity of a vertebrate cell by introducing into a cell the recombinant hTERT polynucleotide encoding an hTERT deletion variant described *supra*. In a related embodiment, the invention provides a cell, such as a human cell or other mammalian cell, comprising a nucleotide sequence that encodes the hTERT deletion variant polypeptide. The invention provides such cells that have an increased proliferative capacity relative to a cell that is otherwise identical but does not comprise the recombinant polynucleotide.

In a different aspect of the invention, an isolated or recombinant hTERT polypeptide that has a deletion of amino acid residues 192-450, 560-565, 637-660, 638-660, 748-766, 748-764, or 1055-1071, where the residue numbering is with reference to the hTERT polypeptide having the sequence provided in Figure 1, is provided. In a related aspect, the invention provides an isolated, recombinant, or substantially purified polynucleotide encoding this polypeptide, which in some embodiments includes a promoter sequence operably linked to the nucleotide sequence encoding the hTERT polypeptide.

The invention also provides a method of reducing telomerase activity in a cell by introducing the polynucleotide described *supra* (i.e., having a deletion of deletion of amino acid residues 192-450, 560-565, 637-660, 638-660, 748-766, 748-764, or 1055-1071) into a cell under conditions in which it is expressed.

In a related embodiment, the hTERT polypeptide has one or more mutations other than, or in addition to, a deletion of at least 25 residues in the regions corresponding to residues 192-323, 200-323, 192-271, 200-271, 222-240, 415-450, 192-323 and 415-450, or 192-271 and 415-450 of hTERT.

In an other embodiment, the invention provides &&& METHOD

DRAWINGS

Figure 1 shows the amino acid sequence of a 1132-residue human telomerase reverse transcriptase (hTERT) protein (SEQ. ID NO:2).

Figure 2 shows the nucleotide sequence of a naturally occurring cDNA encoding the hTERT protein (SEQ. ID NO:1).

DETAILED DESCRIPTION

I. Introduction

Telomerase is a ribonucleoprotein complex (RNP) comprising an RNA component and a catalytic protein component. The catalytic protein component of human telomerase, hereinafter referred to as telomerase reverse transcriptase ("hTERT"), has been cloned, and protein, cDNA and genomic sequences determined. See, e.g., Nakamura et al., 1997, *Science* 277:955, and copending U.S. Patent Applications Serial Nos. 08/912,951 and 08/974,549. The sequence of a full-length native hTERT has been deposited in GenBank (Accession No. AF015950), and plasmid and phage vectors having hTERT coding sequences have been deposited with the American Type Culture Collection, Rockville, Maryland (accession numbers 209024, 209016, and 98505). The catalytic subunit protein of human telomerase has also been referred to as "hEST2" (Meyerson et al., 1997, *Cell* 90:785), "hTCS1" (Kilian et al., 1997, *Hum. Mol. Genet.* 6:2011), "TP2" (Harrington et al., 1997, *Genes Dev.* 11:3109), and "hTERT" (e.g., Greider, 1998, *Curr. Biol.* 8:R178-R181). Human TERT is also described in the aforementioned priority applications and U.S. Patent Application Serial Numbers 08/846,017, 08/844,419, and 08/724,643. The RNA component of human telomerase (hTR) has also been characterized (see U.S. Patent No. 5,583,016). All of the aforementioned applications and publications are incorporated by reference herein in their entirety and for all purposes.

Human TERT is of extraordinary interest and value because, *inter alia*, telomerase activity in human cells and other mammalian cells correlates with cell proliferative capacity, cell immortality, and the development of a neoplastic phenotype. Thus, hTERT polypeptides, including the hTERT variants described herein, and polynucleotides encoding hTERT polypeptides, are used, *inter alia* for conferring a telomerase activity (e.g., telomerase catalytic activity, *infra*) in a telomerase-negative cell such as a cell from a human, a mammal, a vertebrate, or other eukaryote (see, e.g., Bodnar et al., 1998, *Science* 279:349 and copending U.S. Patent Applications Serial Nos. 08/912,951 and 08/974,549). Variants that lack at least one hTERT activity (e.g., telomerase catalytic activity) are used, *inter alia*, to inhibit telomerase activity in a cell (e.g., by acting as "dominant negative mutants"). The hTERT variants and polynucleotides encoding them, as described herein, are similarly useful in screening assays for identifying agents that modulate telomerase activity.

The hTERT variants of the present invention are characterized by one or more deletions or mutations, relative to a naturally occurring hTERT polypeptide, in defined regions of the protein, as

Processive telomerase catalytic activity can be assayed by a variety of methods, including the "conventional assay" (Morin, 1989, *Cell* 59:521), the TRAP assay (U.S. Patent No. 5,629,154; see also, PCT publication WO 97/15687, PCT publication WO 95/13381; Krupp et al. *Nucleic Acids Res.*, 1997, 25: 919; Wright et al., 1995, *Nucl. Acids Res.* 23:3794), the "dot blot immunoassay" (U.S. Patent Application Serial Number 08/833,377), and other assays (e.g., Tatematsu et al., 1996, *Oncogene* 13:2265). The TRAPeze™ Kit (Oncor,

Inc., Gaithersburg, MD) may be used. The telomerase substrate used in these assays may have a natural telomere sequence, or may be have a synthetic oligonucleotide with a different sequence (see, e.g., Morin, 1989, *Cell* 59:521; Morin, 1991, *Nature* 353:454-56).

As used herein, an hTERT variant is considered to have a specified activity if the activity is exhibited by either the hTERT variant polypeptide without an associated hTR RNA or in an hTERT-hTR complex. Each of the hTERT activities described *supra* is also described in detail in copending U.S. Patent Applications Serial Nos. 08/912,951 and 08/974,549.

II. hTERT Variants Described

a) hTERT Variants with Telomerase Catalytic Activity

It has now been demonstrated that large regions of the hTERT protein can be mutated (e.g., deleted) without loss of telomerase catalytic activity. Sites of mutation (e.g., deletion) are described herein with reference to the amino acid sequence provided in Figure 1 and encoded in plasmid pGRN121 (ATCC accession number 209016); however it will be recognized that the same or equivalent mutations may be made in other hTERT polypeptides, e.g., naturally occurring variants such as polymorphic variants, hTERT fusion proteins, hTERT homologs (e.g., from non-human species), and the like. For ease of discussion, the residues of the full-length hTERT protein having a sequence as provided in Figure 1 are referred to herein by number, with the amino-terminal methionine (M) in Figure 1 numbered "1", and the carboxy-terminal aspartic acid (D) numbered "1132".

Regions of the hTERT protein that can be mutated (e.g., deleted) without abolishing telomerase catalytic activity include the regions from amino acid residues 192 to 323 (inclusive) and residues 415 to 450 (inclusive). As is demonstrated in the experiments described *infra*, all or part of either of these regions, or all or part of both of them, can be deleted without abolishing the telomerase catalytic activity of the protein. The regions from amino acid residues 192 to 323 and residues 415 to 450 may be referred to as "nonessential" regions of hTERT (i.e., not essential for telomerase catalytic activity). Thus, in various embodiments, the hTERT variants of the invention comprise deletions of, or other mutations in, these nonessential regions of hTERT. As described in Section IV, *infra*, certain mutations (e.g., deletion of residues 415-450) alter RNA-binding characteristics of the hTERT variant.

Examples of mutations that can be made in the hTERT polypeptides of the invention include deletions, insertions, substitutions, and combination of mutations. Thus, in some embodiments the mutation is a deletion of at least one, typically at least about 10, and often at least about 25, at least about 50, or at least about 100 amino acid residues relative to a naturally occurring hTERT. In alternative embodiments, the mutation is a single amino acid substitution in a "non-essential" region, or a combinations of substitutions. Substitutions may be conservative substitutions or non-conservative substitutions. In still other embodiments, the mutation is an insertion or substitution of amino acids, for example the insertion of residues that encode an epitope tag or novel proteolytic site. Substitutions may be of one or more (e.g., all) of the residues in the above-mentioned regions or may be combined with deletions so that, e.g., a shorter heterologous sequence is a substituted for a longer hTERT sequence. It will be appreciated, as noted *supra*, that in some embodiments the hTERT variant has more than one different type of mutation relative to a naturally occurring hTERT protein (e.g., a deletion and a point mutation).

The hTERT variants of the invention have certain advantages compared to naturally occurring hTERT proteins. In some embodiments, mutations may confer more efficient *in vitro* expression of active hTERT (e.g., in expression systems in which shorter polypeptides are more efficiently expressed than longer polypeptides), may provide sequences that aid in purification (e.g., an epitope tag sequence), or may add a new functional moiety to the hTERT polypeptide (e.g., a 3'→5' exonuclease domain from DNA polymerase I).

As noted *supra*, the hTERT variant polypeptides of the invention comprising mutations (e.g., deletions) in the "non-essential" regions of the hTERT retain telomerase catalytic activity. These variants, and polynucleotides that encode them, are useful in any application for which other catalytically active hTERT proteins (e.g., wild-type hTERT proteins) or polynucleotides may be used, including, *inter alia*, in therapeutic, diagnostic, and screening uses. Exemplary uses of hTERT polypeptides and polynucleotides are described in additional detail in the afore

cited copending applications (e.g., U.S.S.N. 08/912,951 and 08/974,549).

In one embodiment, the hTERT variant of the invention is used to increase the proliferative capacity of a cell by, e.g., increasing telomerase activity in the cell (see, Bodnar et al. *supra*, and copending U.S. Patent Applications Serial Nos. 08/912,951 and 08/974,549 for a detailed description of exemplary methods). Briefly, in one embodiment, a polynucleotide comprising (i) a sequence encoding the hTERT variant polypeptide; (ii) an operably linked promoter (e.g., a heterologous promoter); and, (iii) optionally polyadenylation and termination signals, enhancers, or other regulatory elements, is introduced into a target cell (e.g., by transfection, lipofection, electroporation, or any other suitable method) under conditions in which the hTERT variant polypeptide is expressed. The expression in the cell of the catalytically active hTERT variant of the invention results in increased proliferative capacity (e.g., an immortal phenotype).

In another embodiment, the hTERT variant is used for *in vitro* reconstitution (IVR) of a telomerase ribonucleoprotein (e.g., comprising the hTERT variant polypeptide and a template RNA, e.g., hTR) that has telomerase catalytic activity. *In vitro* reconstitution methods are described in, e.g., Weinrich et al., 1997, *Nat. Genet.* 17:498, and copending U.S. Patent Applications Serial Nos. 08/912,951 and 08/974,549. Briefly, in one embodiment, an expression vector encoding an hTERT variant of the invention is expressed in an *in vitro* expression system (e.g., a coupled transcription-translation reticulocyte lysate system such as that described in U.S. Patent No. 5,324,637). In a particular embodiment, the hTERT variant polypeptide is coexpressed with hTR. In an alternative embodiment, the hTERT variant and hTR are separately expressed and then combined (mixed) *in vitro*. In the latter method, the hTR RNA and/or hTERT polypeptide may be purified before mixing. In this context, the hTERT polypeptide is "purified" when it is separated from at least one other component of the *in vitro* expression system, and it may be purified to homogeneity as determined by standard methods (e.g., SDS-PAGE). The *in vitro* reconstituted (IVR) telomerase has a variety of uses; in particular it is useful for identifying agents that modulate hTERT activity (e.g., drug screening assays).

(b) Deletion Variants Lacking Telomerase Catalytic Activity

In an other aspect, the invention provides hTERT deletion variants that lack telomerase catalytic activity (i.e., having less than 1% of the wild type activity), as well as polynucleotides encoding the variants lacking telomerase catalytic activity. In particular, the invention provides variants comprising one or more of the following deletions relative to wild-type hTERT: residues 192-450, 637-660, 638-660, 748-766, 748-764, and 1055-1071. These variants are referred to herein as "PCA⁻ variants" (processive telomerase catalytic activity minus variants).

The PCA⁻ variant proteins and polynucleotides of the invention lacking telomerase catalytic activity are used in, *inter alia*, therapeutic, screening and other applications. For example, PCA⁻ variants are useful as dominant negative mutants for inhibition of telomerase activity in a cell. In one embodiment, a PCA⁻ variant is introduced into a cell (e.g., by transfection with a polynucleotide expression vector expressing the PCA⁻ variant), resulting in sequestration of a cell component (e.g., hTR) required for accurate telomere elongation. Thus, for example, administration of a polypeptide that binds hTR, a DNA primer, a telomerase-associated protein, or other cell component, but which does not have telomerase catalytic activity, is used to reduce endogenous telomerase

activity in the cell or to otherwise interfere with telomere extension (e.g., by displacing active telomerase from telomeric DNA). Similarly, in certain embodiments, a PCA⁻ variant of the invention having one or several hTRT activities (i.e., other than processive telomerase catalytic activity) is used for screening for agents that specifically modulate (inhibit or activate) a telomerase activity other than telomerase catalytic activity. The use of hTRT variants as dominant negative mutants, and in other applications, is described in detail in copending U.S. Patent Applications Serial Nos. 08/912,951 and 08/974,549.

III. Making hTRT Variants

The hTRT variant polypeptides and polynucleotides of the invention may be produced using any of a variety of techniques known in the art. In one embodiment, a polypeptide having the desired sequence, or a polynucleotide encoding the polypeptide, is chemically synthesized (see, e.g., Roberge, et al., 1995, *Science* 269:202; Brown et al., 1979, *Meth. Enzymol.* 68:109). More often, the hTRT variant polypeptides and polynucleotides of the invention are created by manipulation of a recombinant polynucleotide encoding an hTRT polypeptide. Examples of suitable recombinant polynucleotides include pGRN121, *supra*, and other hTRT cDNA and genomic sequences.

Methods for cloning and manipulation of hTRT encoding nucleic acids (e.g., site-specific mutagenesis, linker scanning mutagenesis, and the like) are well known in the art and are described, for example, in Sambrook et al., 1989, *MOLECULAR CLONING: A LABORATORY MANUAL*, 2ND ED., VOLS. 1-3, Cold Spring Harbor Laboratory, and Ausubel et al., 1997, *CURRENT PROTOCOLS IN MOLECULAR BIOLOGY*, Greene Publishing and Wiley-Interscience, New York. One convenient method for producing a polynucleotide encoding a desired hTRT deletion variant is by restriction digestion and subsequent ligation of a hTRT polynucleotide, to remove a region(s) of the polynucleotide encoding the amino acid residues to be deleted. If desired, restriction sites can be introduced or removed from a synthetic or naturally occurring hTRT gene to facilitate the production and detection of variants.

Typically, the recombinant polynucleotide encoding an hTRT variant of the invention is linked to appropriate regulatory elements (e.g., promoters, enhancers, polyadenylation signals, and the like) and expressed in a cell free system (see, e.g., Weinrich et al., *supra*), in bacteria (e.g., *E. coli*), in *ex vivo* animal cell culture (see, e.g., Bodnar et al., *supra*), in animals or plants (e.g., transgenic organisms or in gene therapy applications), or by any other suitable method. Suitable expression systems are well known in the art and include those described in Weinrich et al., and Bodnar et al., both *supra*, and in e.g., copending U.S. Patent Applications Serial Nos. 08/912,951 and 08/974,549.

Additional hTRT variants of the invention may be made using "DNA shuffling" *in vitro* recombination technology (see, e.g., Crameri et al., 1998, *Nature* 391:288-291; Patten et al., 1997, *Curr. Opin. Biotechnol.* 8:724-733; Stemmer, 1994, *Nature* 370:389-391; Crameri et al., 1996, *Nature Medicine*, 2:1-3; Crameri et al., 1996, *Nature Biotechnology* 14:315-319; WO 95/22625; Stemmer, 1995, *Science* 270:1510; Stemmer et al., 1995, *Gene*, 164, 49-53; Stemmer, 1995, *Bio/Technology*, 13:549-553; Stemmer, 1994, *Proc. Natl. Acad. Sci. USA* 91:10747-10751). The specific deletion variants described *supra*, "wild-type hTRT" and non-human hTRT-homologs may be used in individually or various combinations as starting substrates to produce novel polypeptides with the desired activity. The activity or activities of the resulting polypeptides determined using the assays described in Section I, *supra*.

IV. Exemplary hTRT Variants

a) Generally

Exemplary hTRT variants were created by *in vitro* mutagenesis of polynucleotides encoding a full-length hTRT protein using the method of Perez et al., 1994, *J. Biol. Chem.* 269:22485-87. The mutant polynucleotides were expressed *in vitro* and telomerase reconstituted by *in vitro* mixing of hTRT and human telomerase RNA as described in Weinrich et al., 1997, *supra*. Reconstitution reactions were carried out using 0.5 pmole, 20 pmole, and, in some cases, other amounts of added hTR. Telomerase processive catalytic activity was assayed using a modified TRAP assay (Weinrich et al., 1997, *supra*). The results are summarized in Table 1.

TABLE 1

Deletion Name	Oligo	Amino acids deleted	Activity ¹
pGRN234	RT1 + RT2	none (delete <i>Nco</i> I site)	+
pGRN226	RT3A	192-323	+
RT3	RT3	200-326	+
pGRN237	RT4A	192-271	+
RT4	RT4	200-271	+
pGRN210	LM122-Nuc	222-240	+
pGRN235	RT5	415-450	+
pGRN242	RT3A+RT5	192-326 + 415-450	+
pGRN243	RT4A+RT5	192-271 + 415-450	+
pGRN240	RT3A/5	192-450	-
pGRN238	RT6A	637-660	-
RT6	RT 6	638-660	-
pGRN239	RT8A	748-766	-
RT8	RT8	748-764	-
pGRN241	RT10	1055-1071	-
pGRN236	RT11	1084-1116	-
pGRN209	LM121-WG	930-934	-
pGRN231		560-565	-

¹ "+" = at least 40% activity compared to *in vitro* reconstitution using wild-type hTRT (e.g., encoded by pGRN125; see Weinrich et al., 1997, *supra*)
 "-" = less than 1% activity.

Certain of the hTRT variants described *supra* are altered in their ability to bind hTR. The variants encoded by pGRN235, pGRN242 and pGRN243 exhibited telomerase activity when 20 pmoles hTR (template RNA) was included in the reconstitution reaction, but showed a low or undetectable level of activity when 0.5 pmoles of hTR was used. The variable activity of these variants indicates that these variants have altered (e.g.,

decreased) hTR binding activity. Thus, the region from 415 to 450 is likely involved in RNA binding (e.g., by affecting the conformation of the protein).

This result suggests that the region immediately upstream of residue 415, corresponding to the conserved "CP" domain (Bryan et al., 1998, *Proc. Nat'l. Acad. Sci.* 95:8479-8484) is a region of contact between the hTRT protein and hTR (e.g., corresponding to about residues 405 to 418 as set forth in Figure 1). This conclusion is supported by the relative lack of conservation of sequence when human and mouse TRT sequences are compared in the region corresponding to hTRT residues 415-450.

hTR binding to hTRT was also affected by mutations and deletions in the region 560-565. RNA binding was assayed by adding purified hTR to epitope tagged TRT proteins (i.e., including a FLAG sequence; Immunex Corp, Seattle WA). The hTR and protein were incubated under conditions under which tagged "wild-type" hTRT associates with template RNA (hTR), and the hTRT protein or hTRT-hTR complex (if present) were immunoprecipitated. The precipitated complex was assayed for the presence and amount of associated RNA. Deletion of residues 560-565 dramatically decreased the binding of hTR by hTRT, with the concurrent expected decrease in telomerase activity (see Table 1, pGRN231). Mutation of phenylalanine (F) to alanine (A) mutation at position 561 of hTRT (the "F561A" variant; see, Weinrich et al., 1997, *supra*) resulted in reduced binding of hTR: this variant did not effectively bind hTR in association reactions when hTR was present at 0.5 pmoles, and showed less-than wild-type binding at 20 pmoles hTR. Mutation of tyrosine at 562 to alanine similarly resulted in a loss of hTR binding activity (e.g., about a 70-80% reduction compared to the wild-type sequence). Mutation of threonine at position 564 to alanine resulted in a decrease in RNA binding by approximately 20% compared to wild-type. In contrast, mutation of residues 560 (F) and 565 (E) to alanine did not affect hTR binding. These results indicate that the region from 560-565 is involved in RNA binding, e.g., by providing residues that contact hTR.

As will be apparent to one of skill advised of these results, the telomerase reconstitution may be inhibited using peptides comprising the sequence corresponding the hTRT residues 405-418, 560-565, or fragments thereof, or peptide mimetics of such sequences. Thus, in one embodiment of the present invention, telomerase activity in a cell or an *in vitro* composition in which TRT protein and TR RNA are present, such as a telomerase reconstitution assay, is reduced by introducing to the cell or *in vitro* composition a polypeptide comprising the sequence FFYVTE (SEQ. ID NO:3), a polypeptide comprising the sequence YGVLLKTHCPLRAA (SEQ. ID NO:4), a polypeptide consisting essentially of FFYVTE (SEQ. ID NO:3), a polypeptide consisting essentially of FYVT (SEQ. ID NO:5), a polypeptide consisting essentially of YGVLLKTHCPLRAA (SEQ. ID NO:4), a fragment of at least three residues of the aforementioned polypeptides, or a peptide analog or mimetic of the polypeptide of any of the aforementioned compositions.

Peptide mimetics (or peptide analogs) are well known and are commonly used in the pharmaceutical industry as non-peptide drugs with properties analogous to those of the template polypeptide (Fauchere, 1986, *Adv. Drug Res.* 15:29; Veber et al., 1985, *TINS* p.392; and Evans et al., 1987, *J. Med. Chem.* 30:1229). Generally, peptidomimetics are structurally similar to the paradigm polypeptide having the sequence from hTRT but have one or more peptide linkages optionally replaced by a linkage selected from the group consisting of: -CH₂NH-, -CH₂S-, -CH₂-CH₂-, -CH'CH- (cis and trans), -COCH₂-, -CH(OH)CH₂-, and -CH₂SO-. Peptide mimetics may have significant advantages over polypeptide embodiments of this invention, including, for example: more economical production, greater chemical stability, enhanced pharmacological properties (half-life, absorption, potency, efficacy, etc.), altered specificity (e.g., a broad-spectrum of biological activities), reduced antigenicity, and others. In addition to modifications to the peptide backbone, synthetic or non-naturally occurring amino acids can also be used to substitute for the amino acids present in the polypeptide or in the functional moiety of fusion proteins. Synthetic or

non-naturally occurring amino acids refer to amino acids which do not naturally occur in vivo but which, nevertheless, can be incorporated into the peptide structures described herein. Preferred synthetic amino acids are the d- α -amino acids of naturally occurring l- α -amino acid, mentioned above, as well as non-naturally occurring d- and l- α -amino acids represented by the formula H_2NCHR_5COOH where R_5 is 1) a lower alkyl group, 2) a cycloalkyl group of from 3 to 7 carbon atoms, 3) a heterocycle of from 3 to 7 carbon atoms and 1 to 2 heteroatoms selected from the group consisting of oxygen, sulfur, and nitrogen, 4) an aromatic residue of from 6 to 10 carbon atoms optionally having from 1 to 3 substituents on the aromatic nucleus selected from the group consisting of hydroxyl, lower alkoxy, amino, and carboxyl, 5) -alkylene-Y where alkylene is an alkylene group of from 1 to 7 carbon atoms and Y is selected from the group consisting of (a) hydroxy, (b) amino, (c) cycloalkyl and cycloalkenyl of from 3 to 7 carbon atoms, (d) aryl of from 6 to 10 carbon atoms optionally having from 1 to 3 substituents on the aromatic nucleus selected from the group consisting of hydroxyl, lower alkoxy, amino and carboxyl, (e) heterocyclic of from 3 to 7 carbon atoms and 1 to 2 heteroatoms selected from the group consisting of oxygen, sulfur, and nitrogen, (f) -C(O)R₂ where R₂ is selected from the group consisting of hydrogen, hydroxy, lower alkyl, lower alkoxy, and -NR₃R₄ where R₃ and R₄ are independently selected from the group consisting of hydrogen and lower alkyl, (g) -S(O)_nR₆ where n is an integer from 1 to 2 and R₆ is lower alkyl and with the proviso that R_5 does not define a side chain of a naturally occurring amino acid. Other preferred synthetic amino acids include amino acids wherein the amino group is separated from the carboxyl group by more than one carbon atom such as β -alanine, γ -aminobutyric acid, and the like.

It will also be recognized by those of skill upon reviewing these results that the compositions (e.g., polypeptides and mimetics) described *supra* can be used to identify telomerase association and activity inhibitors other than the disclosed polypeptide and mimetics. These compositions may be used, for example, in rational drug design for e.g., computer modeling of telomerase activity modulators (e.g., modulators that inhibit the association of TRT and TR or that catalyze the disassociation of the telomerase complex), as positive controls in screens for modulators of telomerase activity, or in competition assays with candidate telomerase activity modulators.

b) Methods

Mutagenesis of the hTRT coding sequence of pGRN125 was carried out using the methods described by Perez et al., 1994, *J. Biol. Chem.* 269:22485-87. Most of the deletion mutants were generated from the plasmid pGRN125 (Weinrich et al., 1997, *supra*). Deletion mutants pGRN235 and pGRN236 were made in a secondary round of mutagenesis in an altered pGRN234. pGRN234 was generated by mutating (deleting) the *Nco*I site in pGRN125 (changing CAC to CAT in the histidine residue at position 754) and introducing a new *Nco*I site at the translation start site (ATG). Table 2 shows exemplary oligonucleotides used to generate the plasmids expressing the deletion variants of the invention.

TABLE 2

Oligo Name	Oligo sequence 5'-3'	length	Description	SEQ. ID NO:
RT1	GAAGGCCGCCCCACGGGCACGTCCGC	25	Mutagenesis oligo to delete Nco I site from pGRN125	6
RT2	CCCGGCCACCCCAGCCATGGCGCGCGCTCCCC		Mutagenesis oligo to create Nco I site @ ATG of pGRN 125	7
RT5	TACGGGGTGCTCCTCAAGACGCAC TGCCCGCTGCTCCGCCAGCACAGC AGCCCCCTGGCAG	60	Mutagenesis oligo to create a deletion of aa 415-450 in pGRN125	8
RT10	TACTCCATCCTGAAAGCCAAGAAGCAGGGCTGTGCCACCAAGCATTC CTGCTCAAGCTG	60	Mutagenesis oligo to create a deletion of aa 1055-1071 in pGRN125	9
RT11	CTGTGCCACCAAGCATTCTGCTC AAGCTGGCCGCAGCCAACCCGGC ACTGCCCTCAGAC	60	Mutagenesis oligo to create a deletion of aa 1083-1116 in pGRN125. Oligo creates a NheI site.	10
RT3A	ACTCAGGCCCGGCCCGGCCACACGCTAGCGAGACCAAGCACTTCCTCTACTCCTCAGGC	60	Mutagenesis oligo to create a deletion of aa 192-323 in pGRN125. Oligo creates a NheI site.	11
RT4A	ACTCAGGCCCGGCCCGGCCACACGCTAGCGTGGTGTACCTGCCAGACCCGCCGAAGAA	60	Mutagenesis oligo to create a deletion of aa 192-271 in pGRN125. Oligo creates a NheI site.	12
RT6A	ATCCCCAAGCCTGACGGGCTGCGGCCGATTGTTAACATGCTGTTCAAGCTGCTCAACTACGAGCGGGCG	69	Mutagenesis oligo to create a deletion of aa 638-660 in pGRN125. Oligo creates a Hpa I site.	13
RT8A	ACGTAAGTGCCTGCGTCCGCTATGCCGTGGTACAGATCTCCAGCCGTACATGCGACAGTTCTGTG	63	Mutagenesis oligo to create a deletion of aa 748-766 in pGRN125. Oligo creates a Bgl II site.	14
RT3A/5	ACTCAGGCCCGGCCCGGCCACACGCTAGCCTGCTCCGCCAGCACAGCAGCCCCCTGGCAG	60	Mutagenesis oligo to create a deletion of aa 192-450 in pGRN125. Oligo creates a NheI site.	15
LM121-WG	GTTCAAGTGCCTGCGGCCCGGCCCTATCCCTCTAGATACCCGGACCCTGGAGGTGCAGAGCGAC	63	Mutagenesis oligo to delete aa 930-934. Oligo introduces a new XbaI site	16
LM122-Nuc	CCCTGGGCCTGCCAGCCCCGGGTGCCGGCGCTGCCCTGAGCCGGA GCGG	50	Mutagenesis oligo to delete aa 222-240. Oligo introduces a new Nae I site	17
RT3	GCTAGTGGACCCCGAAGGCGTCTGGATGCGAGACCAAGCACTTCCTCTACTCCTCAGGC	60	Mutagenesis oligo to create a deletion of aa200-323 in pGRN125	18
RT4	GCTAGTGGACCCCGAAGGCGTCTGGATGCGTGGTGTACCTGCCAGACCCGCCGAAGAA	60	Mutagenesis oligo to create a deletion of aa 200-271 in pGRN125	19
RT6	GACGGGCTGCGGCCGATTGTGAACATGGACCTGTTCAAGCGTGTCAACTACGAGCGGGCG	60	Mutagenesis oligo to create a deletion of aa 638-660 in pGRN125	20
RT8	ACGTAAGTGCCTGCGTCCGCTATGCCGTGGTACACCTTGACAGACCTCCAGCCGTACATGCGA	60	Mutagenesis oligo to create a deletion of aa 748-764 in pGRN125	21

V. Definitions

The following terms are defined *infra* to provide additional guidance to one of skill in the practice of the invention:

As used herein, a polypeptide region in a first polypeptide "corresponds" to a region in a second polypeptide when the amino acid sequences of the two regions, or flanking the two regions, are the same or substantially identical. Sequences can be aligned by inspection (e.g., alignment of identical sequences) or by computer implemented alignment of the two sequences. Thus, for example, the residues 192 to 323 of the hTRT polypeptide having the sequence set forth in Figure 1 "correspond" to residues in the same position in a hTRT polypeptide that differs from the Figure 1 sequence due to polymorphic variation, or other mutations or deletions (e.g., when the two polypeptides are optimally aligned). Alignments may also be carried out using the GAP computer program, version 6.0 (Devereux et al, 1984, *Nucl. Acid. Res.* 12:387; available from the University of Wisconsin Genetics Computer Group, Madison, WI). The GAP program utilizes the alignment method of Needleham and Wunsch, 1970 *J. Mol. Biol.* 48: 443-453 as revised by Smith and Waterman, 1981, *Adv. Appl. Math* 2:482. The preferred default parameters for the GAP program include (1) the weighted comparison matrix of Gribskov and Burgess, 1986, *Nucl. Acid. Res.* 14:6745 as described by Schwartz and Dayhoff, eds., 1979, *ATLAS OF PROTEIN SEQUENCE AND STRUCTURE*, National Biomedical Research Foundation, pp. 353-358 (2) a penalty of 3.0 for each gap and an additional 0.10 penalty for each symbol in each gap; and (3) no penalty for end gaps. Alternatively, alignments can be carried out using the BLAST algorithm, which is described in Altschul et al., 1990, *J. Mol. Biol.* 215:403-410 using as defaults a wordlength (W) of 11, the BLOSUM62 scoring matrix (see Henikoff & Henikoff, 1989, *Proc. Natl. Acad. Sci. USA* 89:10915); alignments (B) of 50, expectation (E) of 10, M=5, and N=-4. A modification of BLAST, the "Gapped BLAST" allows gaps to be introduced into the alignments that are returned (Altschul et al., 1997, *Nucleic Acids Res* 1:3389-3402). Software for performing BLAST analyses is publicly available through the National Center for Biotechnology Information (<http://www.ncbi.nlm.nih.gov/>).

When referring to an "activity" of an hTRT variant, a variant is considered to be active in an assay of it displays at least 40% of the activity characteristic of the hTRT polypeptide having the sequence set forth in Fig. 1 ("wild type"). A variant is considered to lack activity when it has less than 1% of the "wild type" activity. A variant with greater than 1% activity and less than 40% activity has "intermediate activity."

As used herein, "conservative substitution," refers to substitution of amino acids with other amino acids having similar properties (e.g., acidic, basic, positively or negatively charged, polar or non-polar). The following six groups each contain amino acids that are conservative substitutions for one another: 1) alanine (A), serine (S), threonine (T); 2) aspartic acid (D), glutamic acid (E); 3) asparagine (N), glutamine (Q); 4) arginine (R), lysine (K); 5) isoleucine (I), leucine (L), methionine (M), valine (V); and 6) phenylalanine (F), tyrosine (Y), tryptophan (W) (see also, Creighton, 1984, *PROTEINS*, W. H. Freeman and Company).

All publications and patent documents cited in this application are incorporated by reference in their entirety and for all purposes to the same extent as if each individual publication or patent document were so individually denoted.

SEQUENCE LISTING

<110> Morin, Gregg B.
Geron Corporation

<120> Human Telomerase Catalytic Subunit Variants

<130> 018/258c

<140> 00/000,000

<141> 2001-00-00

<140> US 09/128,354

<141> 1998-08-03

<150> US 09/052,864

<151> 1998-03-31

<160> 21

<170> PatentIn Ver. 2.0

<210> 1

<211> 4015

<212> DNA

<213> Homo sapiens

<220>

<221> CDS

<222> (56)..(3454)

<223> human telomerase reverse transcriptase (hTERT) cDNA

<400> 1

```
gcagcgctgc gtcctgctgc gcacgtggga agccctggcc ccggccaccc ccgcg atg 58
                                     Met
                                     1

ccg cgc gct ccc cgc tgc cga gcc gtg cgc tcc ctg ctg cgc agc cac 106
Pro Arg Ala Pro Arg Cys Arg Ala Val Arg Ser Leu Leu Arg Ser His
      5              10              15

tac cgc gag gtg ctg ccg ctg gcc acg ttc gtg cgg cgc ctg ggg ccc 154
Tyr Arg Glu Val Leu Pro Leu Ala Thr Phe Val Arg Arg Leu Gly Pro
      20              25              30

cag ggc tgg cgg ctg gtg cag cgc ggg gac ccg gcg gct ttc cgc gcg 202
Gln Gly Trp Arg Leu Val Gln Arg Gly Asp Pro Ala Ala Phe Arg Ala
      35              40              45

ctg gtg gcc cag tgc ctg gtg tgc gtg ccc tgg gac gca cgg ccg ccc 250
Leu Val Ala Gln Cys Leu Val Cys Val Pro Trp Asp Ala Arg Pro Pro
      50              55              60              65

ccc gcc gcc ccc tcc ttc cgc cag gtg tcc tgc ctg aag gag ctg gtg 298
Pro Ala Ala Pro Ser Phe Arg Gln Val Ser Cys Leu Lys Glu Leu Val
      70              75              80

gcc cga gtg ctg cag agg ctg tgc gag cgc ggc gcg aag aac gtg ctg 346
Ala Arg Val Leu Gln Arg Leu Cys Glu Arg Gly Ala Lys Asn Val Leu
      85              90              95

gcc ttc ggc ttc gcg ctg ctg gac ggg gcc cgc ggg ggc ccc ccc gag 394
Ala Phe Gly Phe Ala Leu Leu Asp Gly Ala Arg Gly Gly Pro Pro Glu
      100              105              110

gcc ttc acc acc agc gtg cgc agc tac ctg ccc aac acg gtg acc gac 442
```

Ala	Phe	Thr	Thr	Ser	Val	Arg	Ser	Tyr	Leu	Pro	Asn	Thr	Val	Thr	Asp		
115						120					125						
gca	ctg	cgg	ggg	agc	ggg	gcg	tgg	ggg	ctg	ctg	ctg	cgc	cgc	gtg	ggc	490	
Ala	Leu	Arg	Gly	Ser	Gly	Ala	Trp	Gly	Leu	Leu	Leu	Arg	Arg	Val	Gly		
130					135				140						145		
gac	gac	gtg	ctg	gtt	cac	ctg	ctg	gca	cgc	tgc	gcg	ctc	ttt	gtg	ctg	538	
Asp	Asp	Val	Leu	Val	His	Leu	Leu	Ala	Arg	Cys	Ala	Leu	Phe	Val	Leu		
				150					155					160			
gtg	gct	ccc	agc	tgc	gcc	tac	cag	gtg	tgc	ggg	ccg	ccg	ctg	tac	cag	586	
Val	Ala	Pro	Ser	Cys	Ala	Tyr	Gln	Val	Cys	Gly	Pro	Pro	Leu	Tyr	Gln		
			165				170						175				
ctc	ggc	gct	gcc	act	cag	gcc	cgg	ccc	ccg	cca	cac	gct	agt	gga	ccc	634	
Leu	Gly	Ala	Ala	Thr	Gln	Ala	Arg	Pro	Pro	Pro	His	Ala	Ser	Gly	Pro		
		180					185					190					
cga	agg	cgt	ctg	gga	tgc	gaa	cgg	gcc	tgg	aac	cat	agc	gtc	agg	gag	682	
Arg	Arg	Arg	Leu	Gly	Cys	Glu	Arg	Ala	Trp	Asn	His	Ser	Val	Arg	Glu		
		195				200					205						
gcc	ggg	gtc	ccc	ctg	ggc	ctg	cca	gcc	ccg	ggt	gcg	agg	agg	cgc	ggg	730	
Ala	Gly	Val	Pro	Leu	Gly	Leu	Pro	Ala	Pro	Gly	Ala	Arg	Arg	Arg	Gly		
210					215				220						225		
ggc	agt	gcc	agc	cga	agt	ctg	ccg	ttg	ccc	aag	agg	ccc	agg	cgt	ggc	778	
Gly	Ser	Ala	Ser	Arg	Ser	Leu	Pro	Leu	Pro	Lys	Arg	Pro	Arg	Arg	Gly		
				230					235					240			
gct	gcc	cct	gag	ccg	gag	cgg	acg	ccc	gtt	ggg	cag	ggg	tcc	tgg	gcc	826	
Ala	Ala	Pro	Glu	Pro	Glu	Arg	Thr	Pro	Val	Gly	Gln	Gly	Ser	Trp	Ala		
			245					250					255				
cac	ccg	ggc	agg	acg	cgt	gga	ccg	agt	gac	cgt	ggt	ttc	tgt	gtg	gtg	874	
His	Pro	Gly	Arg	Thr	Arg	Gly	Pro	Ser	Asp	Arg	Gly	Phe	Cys	Val	Val		
		260					265					270					
tca	cct	gcc	aga	ccc	gcc	gaa	gaa	gcc	acc	tct	ttg	gag	ggt	gcg	ctc	922	
Ser	Pro	Ala	Arg	Pro	Ala	Glu	Glu	Ala	Thr	Ser	Leu	Glu	Gly	Ala	Leu		
		275				280					285						
tct	ggc	acg	cgc	cac	tcc	cac	cca	tcc	gtg	ggc	cgc	cag	cac	cac	gcg	970	
Ser	Gly	Thr	Arg	His	Ser	His	Pro	Ser	Val	Gly	Arg	Gln	His	His	Ala		
		290			295					300					305		
ggc	ccc	cca	tcc	aca	tgc	cgg	cca	cca	cgt	ccc	tgg	gac	acg	cct	tgt	1018	
Gly	Pro	Pro	Ser	Thr	Ser	Arg	Pro	Pro	Arg	Pro	Trp	Asp	Thr	Pro	Cys		
				310					315					320			
ccc	ccg	gtg	tac	gcc	gag	acc	aag	cac	ttc	ctc	tac	tcc	tca	ggc	gac	1066	
Pro	Pro	Val	Tyr	Ala	Glu	Thr	Lys	His	Phe	Leu	Tyr	Ser	Ser	Gly	Asp		
			325					330					335				
aag	gag	cag	ctg	cgg	ccc	tcc	ttc	cta	ctc	agc	tct	ctg	agg	ccc	agc	1114	
Lys	Glu	Gln	Leu	Arg	Pro	Ser	Phe	Leu	Leu	Ser	Ser	Leu	Arg	Pro	Ser		
		340					345					350					
ctg	act	ggc	gct	cgg	agg	ctc	gtg	gag	acc	atc	ttt	ctg	ggt	tcc	agg	1162	
Leu	Thr	Gly	Ala	Arg	Arg	Leu	Val	Glu	Thr	Ile	Phe	Leu	Gly	Ser	Arg		
		355				360				365							
ccc	tgg	atg	cca	ggg	act	ccc	cgc	agg	ttg	ccc	cgc	ctg	ccc	cag	cgc	1210	
Pro	Trp	Met	Pro	Gly	Thr	Pro	Arg	Arg	Leu	Pro	Arg	Leu	Pro	Gln	Arg		
		370			375					380					385		
tac	tgg	caa	atg	cgg	ccc	ctg	ttt	ctg	gag	ctg	ctt	ggg	aac	cac	gcg	1258	

Tyr Trp Gln Met Arg Pro Leu Phe Leu Glu Leu Leu Gly Asn His Ala	
390 395 400	
cag tgc ccc tac ggg gtg ctc ctc aag acg cac tgc ccg ctg cga gct	1306
Gln Cys Pro Tyr Gly Val Leu Leu Lys Thr His Cys Pro Leu Arg Ala	
405 410 415	
gcg gtc acc cca gca gcc ggt gtc tgt gcc cgg gag aag ccc cag ggc	1354
Ala Val Thr Pro Ala Ala Gly Val Cys Ala Arg Glu Lys Pro Gln Gly	
420 425 430	
tct gtg gcg gcc ccc gag gag gag gac aca gac ccc cgt cgc ctg gtg	1402
Ser Val Ala Ala Pro Glu Glu Glu Asp Thr Asp Pro Arg Arg Leu Val	
435 440 445	
cag ctg ctc cgc cag cac agc agc ccc tgg cag gtg tac ggc ttc gtg	1450
Gln Leu Leu Arg Gln His Ser Ser Pro Trp Gln Val Tyr Gly Phe Val	
450 455 460 465	
cgg gcc tgc ctg cgc cgg ctg gtg ccc cca ggc ctc tgg ggc tcc agg	1498
Arg Ala Cys Leu Arg Arg Leu Val Pro Pro Gly Leu Trp Gly Ser Arg	
470 475 480	
cac aac gaa cgc cgc ttc ctc agg aac acc aag aag ttc atc tcc ctg	1546
His Asn Glu Arg Arg Phe Leu Arg Asn Thr Lys Lys Phe Ile Ser Leu	
485 490 495	
ggg aag cat gcc aag ctc tcg ctg cag gag ctg acg tgg aag atg agc	1594
Gly Lys His Ala Lys Leu Ser Leu Gln Glu Leu Thr Trp Lys Met Ser	
500 505 510	
gtg cgg gac tgc gct tgg ctg cgc agg agc cca ggg gtt ggc tgt gtt	1642
Val Arg Asp Cys Ala Trp Leu Arg Arg Ser Pro Gly Val Gly Cys Val	
515 520 525	
ccg gcc gca gag cac cgt ctg cgt gag gag atc ctg gcc aag ttc ctg	1690
Pro Ala Ala Glu His Arg Leu Arg Glu Glu Ile Leu Ala Lys Phe Leu	
530 535 540 545	
cac tgg ctg atg agt gtg tac gtc gtc gag ctg ctc agg tct ttc ttt	1738
His Trp Leu Met Ser Val Tyr Val Val Glu Leu Leu Arg Ser Phe Phe	
550 555 560	
tat gtc acg gag acc acg ttt caa aag aac agg ctc ttt ttc tac cgg	1786
Tyr Val Thr Glu Thr Thr Phe Gln Lys Asn Arg Leu Phe Phe Tyr Arg	
565 570 575	
aag agt gtc tgg agc aag ttg caa agc att gga atc aga cag cac ttg	1834
Lys Ser Val Trp Ser Lys Leu Gln Ser Ile Gly Ile Arg Gln His Leu	
580 585 590	
aag agg gtg cag ctg cgg gag ctg tcg gaa gca gag gtc agg cag cat	1882
Lys Arg Val Gln Leu Arg Glu Leu Ser Glu Ala Glu Val Arg Gln His	
595 600 605	
cgg gaa gcc agg ccc gcc ctg ctg acg tcc aga ctc cgc ttc atc ccc	1930
Arg Glu Ala Arg Pro Ala Leu Leu Thr Ser Arg Leu Arg Phe Ile Pro	
610 615 620 625	
aag cct gac ggg ctg cgg ccg att gtg aac atg gac tac gtc gtg gga	1978
Lys Pro Asp Gly Leu Arg Pro Ile Val Asn Met Asp Tyr Val Val Gly	
630 635 640	
gcc aga acg ttc cgc aga gaa aag agg gcc gag cgt ctc acc tcg agg	2026
Ala Arg Thr Phe Arg Arg Glu Lys Arg Ala Glu Arg Leu Thr Ser Arg	
645 650 655	
gtg aag gca ctg ttc agc gtg ctc aac tac gag cgg gcg cgg cgc ccc	2074

Val	Lys	Ala	Leu	Phe	Ser	Val	Leu	Asn	Tyr	Glu	Arg	Ala	Arg	Arg	Pro		
		660					665					670					
ggc	ctc	ctg	ggc	gcc	tct	gtg	ctg	ggc	ctg	gac	gat	atc	cac	agg	gcc	2122	
Gly	Leu	Leu	Gly	Ala	Ser	Val	Leu	Gly	Leu	Asp	Asp	Ile	His	Arg	Ala		
		675				680					685						
tgg	cgc	acc	ttc	gtg	ctg	cgt	gtg	cgg	gcc	cag	gac	ccg	ccg	cct	gag	2170	
Trp	Arg	Thr	Phe	Val	Leu	Arg	Val	Arg	Ala	Gln	Asp	Pro	Pro	Pro	Glu		
						695				700					705		
ctg	tac	ttt	gtc	aag	gtg	gat	gtg	acg	ggc	gcg	tac	gac	acc	atc	ccc	2218	
Leu	Tyr	Phe	Val	Lys	Val	Asp	Val	Thr	Gly	Ala	Tyr	Asp	Thr	Ile	Pro		
				710					715					720			
cag	gac	agg	ctc	acg	gag	gtc	atc	gcc	agc	atc	atc	aaa	ccc	cag	aac	2266	
Gln	Asp	Arg	Leu	Thr	Glu	Val	Ile	Ala	Ser	Ile	Ile	Lys	Pro	Gln	Asn		
				725				730					735				
acg	tac	tgc	gtg	cgt	cgg	tat	gcc	gtg	gtc	cag	aag	gcc	gcc	cat	ggg	2314	
Thr	Tyr	Cys	Val	Arg	Arg	Tyr	Gla	Val	Val	Gln	Lys	Ala	Ala	His	Gly		
			740				745					750					
cac	gtc	cgc	aag	gcc	ttc	aag	agc	cac	gtc	tct	acc	ttg	aca	gac	ctc	2362	
His	Val	Arg	Lys	Ala	Phe	Lys	Ser	His	Val	Ser	Thr	Leu	Thr	Asp	Leu		
						760					765						
cag	ccg	tac	atg	cga	cag	ttc	gtg	gct	cac	ctg	cag	gag	acc	agc	ccg	2410	
Gln	Pro	Tyr	Met	Arg	Gln	Phe	Val	Ala	His	Leu	Gln	Glu	Thr	Ser	Pro		
						775				780					785		
ctg	agg	gat	gcc	gtc	gtc	atc	gag	cag	agc	tcc	tcc	ctg	aat	gag	gcc	2458	
Leu	Arg	Asp	Ala	Val	Val	Ile	Glu	Gln	Ser	Ser	Ser	Leu	Asn	Glu	Ala		
						790			795					800			
agc	agt	ggc	ctc	ttc	gac	gtc	ttc	cta	cgc	ttc	atg	tgc	cac	cac	gcc	2506	
Ser	Ser	Gly	Leu	Phe	Asp	Val	Phe	Leu	Arg	Phe	Met	Cys	His	His	Ala		
				805				810					815				
gtg	cgc	atc	agg	ggc	aag	tcc	tac	gtc	cag	tgc	cag	ggg	atc	ccg	cag	2554	
Val	Arg	Ile	Arg	Gly	Lys	Ser	Tyr	Val	Gln	Cys	Gln	Gly	Ile	Pro	Gln		
							825					830					
ggc	tcc	atc	ctc	tcc	acg	ctg	ctc	tgc	agc	ctg	tgc	tac	ggc	gac	atg	2602	
Gly	Ser	Ile	Leu	Ser	Thr	Leu	Leu	Cys	Ser	Leu	Cys	Tyr	Gly	Asp	Met		
						840					845						
gag	aac	aag	ctg	ttt	gcg	ggg	att	cgg	cgg	gac	ggg	ctg	ctc	ctg	cgt	2650	
Glu	Asn	Lys	Leu	Phe	Ala	Gly	Ile	Arg	Arg	Asp	Gly	Leu	Leu	Leu	Arg		
						855				860					865		
ttg	gtg	gat	gat	ttc	ttg	ttg	gtg	aca	cct	cac	ctc	acc	cac	gcg	aaa	2698	
Leu	Val	Asp	Asp	Phe	Leu	Leu	Val	Thr	Pro	His	Leu	Thr	His	Ala	Lys		
								875						880			
acc	ttc	ctc	agg	acc	ctg	gtc	cga	ggt	gtc	cct	gag	tat	ggc	tgc	gtg	2746	
Thr	Phe	Leu	Arg	Thr	Leu	Val	Arg	Gly	Val	Pro	Glu	Tyr	Gly	Cys	Val		
								890					895				
gtg	aac	ttg	cgg	aag	aca	gtg	gtg	aac	ttc	cct	gta	gaa	gac	gag	gcc	2794	
Val	Asn	Leu	Arg	Lys	Thr	Val	Val	Asn	Phe	Pro	Val	Glu	Asp	Glu	Ala		
						905						910					
ctg	ggt	ggc	acg	gct	ttt	gtt	cag	atg	ccg	gcc	cac	ggc	cta	ttc	ccc	2842	
Leu	Gly	Gly	Thr	Ala	Phe	Val	Gln	Met	Pro	Ala	His	Gly	Leu	Phe	Pro		
						920					925						
tgg	tgc	ggc	ctg	ctg	ctg	gat	acc	cgg	acc	ctg	gag	gtg	cag	agc	gac	2890	

Trp	Cys	Gly	Leu	Leu	Leu	Asp	Thr	Arg	Thr	Leu	Glu	Val	Gln	Ser	Asp		
930						935					940				945		
tac	tcc	agc	tat	gcc	cgg	acc	tcc	atc	aga	gcc	agt	ctc	acc	ttc	aac	2938	
Tyr	Ser	Ser	Tyr	Ala	Arg	Thr	Ser	Ile	Arg	Ala	Ser	Leu	Thr	Phe	Asn		
				950					955					960			
cgc	ggc	ttc	aag	gct	ggg	agg	aac	atg	cgt	cgc	aaa	ctc	ttt	ggg	gtc	2986	
Arg	Gly	Phe	Lys	Ala	Gly	Arg	Asn	Met	Arg	Arg	Lys	Leu	Phe	Gly	Val		
			965					970					975				
ttg	cgg	ctg	aag	tgt	cac	agc	ctg	ttt	ctg	gat	ttg	cag	gtg	aac	agc	3034	
Leu	Arg	Leu	Lys	Cys	His	Ser	Leu	Phe	Leu	Asp	Leu	Gln	Val	Asn	Ser		
			980				985					990					
ctc	cag	acg	gtg	tgc	acc	aac	atc	tac	aag	atc	ctc	ctg	ctg	cag	gcg	3082	
Leu	Gln	Thr	Val	Cys	Thr	Asn	Ile	Tyr	Lys	Ile	Leu	Leu	Leu	Gln	Ala		
	995					1000				1005							
tac	agg	ttt	cac	gca	tgt	gtg	ctg	cag	ctc	cca	ttt	cat	cag	caa	gtt	3130	
Tyr	Arg	Phe	His	Ala	Cys	Val	Leu	Gln	Leu	Pro	Phe	His	Gln	Gln	Val		
1010				1015					1020					1025			
tgg	aag	aac	ccc	aca	ttt	ttc	ctg	cgc	gtc	atc	tct	gac	acg	gcc	tcc	3178	
Trp	Lys	Asn	Pro	Thr	Phe	Phe	Leu	Arg	Val	Ile	Ser	Asp	Thr	Ala	Ser		
			1030					1035					1040				
ctc	tgc	tac	tcc	atc	ctg	aaa	gcc	aag	aac	gca	ggg	atg	tcg	ctg	ggg	3226	
Leu	Cys	Tyr	Ser	Ile	Leu	Lys	Ala	Lys	Asn	Ala	Gly	Met	Ser	Leu	Gly		
			1045				1050					1055					
gcc	aag	ggc	gcc	gcc	ggc	cct	ctg	ccc	tcc	gag	gcc	gtg	cag	tgg	ctg	3274	
Ala	Lys	Gly	Ala	Ala	Gly	Pro	Leu	Pro	Ser	Glu	Ala	Val	Gln	Trp	Leu		
	1060					1065					1070						
tgc	cac	caa	gca	ttc	ctg	ctc	aag	ctg	act	cga	cac	cgt	gtc	acc	tac	3322	
Cys	His	Gln	Ala	Phe	Leu	Leu	Lys	Leu	Thr	Arg	His	Arg	Val	Thr	Tyr		
	1075				1080				1085								
gtg	cca	ctc	ctg	ggg	tca	ctc	agg	aca	gcc	cag	acg	cag	ctg	agt	cgg	3370	
Val	Pro	Leu	Leu	Gly	Ser	Leu	Arg	Thr	Ala	Gln	Thr	Gln	Leu	Ser	Arg		
1090				1095				1100				1105					
aag	ctc	ccg	ggg	acg	acg	ctg	act	gcc	ctg	gag	gcc	gca	gcc	aac	ccg	3418	
Lys	Leu	Pro	Gly	Thr	Leu	Thr	Ala	Leu	Glu	Ala	Ala	Ala	Ala	Asn	Pro		
			1110				1115					1120					
gca	ctg	ccc	tca	gac	ttc	aag	acc	atc	ctg	gac	tga	tggccaccg				3464	
Ala	Leu	Pro	Ser	Asp	Phe	Lys	Thr	Ile	Leu	Asp							
			1125				1130										
cccacagcca	ggccgagagc	agacaccagc	agccctgtca	cgccgggctc	tacgtcccag											3524	
ggagggaggg	gcggcccaca	cccaggcccg	caccgctggg	agtctgaggc	ctgagtgagt											3584	
gtttggccga	ggcctgcatg	tccggctgaa	ggctgagtgt	ccggctgagg	cctgagcgag											3644	
tgtccagcca	agggctgagt	gtccagcaca	cctgccgtct	tcacttcccc	acaggctggc											3704	
gctcggctcc	acccagggc	cagcttttcc	tcaccaggag	cccggcttcc	actccccaca											3764	
taggaatagt	ccatccccag	attcgccatt	gttcaccct	cgccctgcc	tcctttgcct											3824	
tccaccccca	ccatccaggt	ggagaccctg	agaaggaccc	tgggagctct	gggaatttgg											3884	
agtgacaaa	ggtgtgccct	gtacacaggc	gaggaccctg	cacctggatg	ggggtccctg											3944	
tgggtcaa	at	tggggggagg	tgctgtggga	gtaaaatact	gaatatatga	gtttttcagt										4004	

tttgaaaaa a

4015

<210> 2
<211> 1132
<212> PRT
<213> Homo sapiens

<400> 2

```
Met Pro Arg Ala Pro Arg Cys Arg Ala Val Arg Ser Leu Leu Arg Ser
 1           5           10           15

His Tyr Arg Glu Val Leu Pro Leu Ala Thr Phe Val Arg Arg Leu Gly
          20           25           30

Pro Gln Gly Trp Arg Leu Val Gln Arg Gly Asp Pro Ala Ala Phe Arg
          35           40           45

Ala Leu Val Ala Gln Cys Leu Val Cys Val Pro Trp Asp Ala Arg Pro
 50           55           60

Pro Pro Ala Ala Pro Ser Phe Arg Gln Val Ser Cys Leu Lys Glu Leu
 65           70           75           80

Val Ala Arg Val Leu Gln Arg Leu Cys Glu Arg Gly Ala Lys Asn Val
          85           90           95

Leu Ala Phe Gly Phe Ala Leu Leu Asp Gly Ala Arg Gly Gly Pro Pro
          100          105          110

Glu Ala Phe Thr Thr Ser Val Arg Ser Tyr Leu Pro Asn Thr Val Thr
          115          120          125

Asp Ala Leu Arg Gly Ser Gly Ala Trp Gly Leu Leu Leu Arg Arg Val
          130          135          140

Gly Asp Asp Val Leu Val His Leu Leu Ala Arg Cys Ala Leu Phe Val
          145          150          155          160

Leu Val Ala Pro Ser Cys Ala Tyr Gln Val Cys Gly Pro Pro Leu Tyr
          165          170          175

Gln Leu Gly Ala Ala Thr Gln Ala Arg Pro Pro Pro His Ala Ser Gly
          180          185          190

Pro Arg Arg Arg Leu Gly Cys Glu Arg Ala Trp Asn His Ser Val Arg
          195          200          205

Glu Ala Gly Val Pro Leu Gly Leu Pro Ala Pro Gly Ala Arg Arg Arg
          210          215          220

Gly Gly Ser Ala Ser Arg Ser Leu Pro Leu Pro Lys Arg Pro Arg Arg
          225          230          235          240

Gly Ala Ala Pro Glu Pro Glu Arg Thr Pro Val Gly Gln Gly Ser Trp
          245          250          255

Ala His Pro Gly Arg Thr Arg Gly Pro Ser Asp Arg Gly Phe Cys Val
          260          265          270

Val Ser Pro Ala Arg Pro Ala Glu Glu Ala Thr Ser Leu Glu Gly Ala
          275          280          285

Leu Ser Gly Thr Arg His Ser His Pro Ser Val Gly Arg Gln His His
          290          295          300

Ala Gly Pro Pro Ser Thr Ser Arg Pro Pro Arg Pro Trp Asp Thr Pro
```

305	310	315	320
Cys Pro Pro Val Tyr Ala Glu Thr Lys His Phe Leu Tyr Ser Ser Gly	325	330	335
Asp Lys Glu Gln Leu Arg Pro Ser Phe Leu Leu Ser Ser Leu Arg Pro	340	345	350
Ser Leu Thr Gly Ala Arg Arg Leu Val Glu Thr Ile Phe Leu Gly Ser	355	360	365
Arg Pro Trp Met Pro Gly Thr Pro Arg Arg Leu Pro Arg Leu Pro Gln	370	375	380
Arg Tyr Trp Gln Met Arg Pro Leu Phe Leu Glu Leu Leu Gly Asn His	385	390	400
Ala Gln Cys Pro Tyr Gly Val Leu Leu Lys Thr His Cys Pro Leu Arg	405	410	415
Ala Ala Val Thr Pro Ala Ala Gly Val Cys Ala Arg Glu Lys Pro Gln	420	425	430
Gly Ser Val Ala Ala Pro Glu Glu Glu Asp Thr Asp Pro Arg Arg Leu	435	440	445
Val Gln Leu Leu Arg Gln His Ser Ser Pro Trp Gln Val Tyr Gly Phe	450	455	460
Val Arg Ala Cys Leu Arg Arg Leu Val Pro Pro Gly Leu Trp Gly Ser	465	470	475
Arg His Asn Glu Arg Arg Phe Leu Arg Asn Thr Lys Lys Phe Ile Ser	485	490	495
Leu Gly Lys His Ala Lys Leu Ser Leu Gln Glu Leu Thr Trp Lys Met	500	505	510
Ser Val Arg Asp Cys Ala Trp Leu Arg Arg Ser Pro Gly Val Gly Cys	515	520	525
Val Pro Ala Ala Glu His Arg Leu Arg Glu Glu Ile Leu Ala Lys Phe	530	535	540
Leu His Trp Leu Met Ser Val Tyr Val Val Glu Leu Leu Arg Ser Phe	545	550	555
Phe Tyr Val Thr Glu Thr Thr Phe Gln Lys Asn Arg Leu Phe Phe Tyr	565	570	575
Arg Lys Ser Val Trp Ser Lys Leu Gln Ser Ile Gly Ile Arg Gln His	580	585	590
Leu Lys Arg Val Gln Leu Arg Glu Leu Ser Glu Ala Glu Val Arg Gln	595	600	605
His Arg Glu Ala Arg Pro Ala Leu Leu Thr Ser Arg Leu Arg Phe Ile	610	615	620
Pro Lys Pro Asp Gly Leu Arg Pro Ile Val Asn Met Asp Tyr Val Val	625	630	635
Gly Ala Arg Thr Phe Arg Arg Glu Lys Arg Ala Glu Arg Leu Thr Ser	645	650	655
Arg Val Lys Ala Leu Phe Ser Val Leu Asn Tyr Glu Arg Ala Arg Arg	660	665	670

Pro Gly Leu Leu Gly Ala Ser Val Leu Gly Leu Asp Asp Ile His Arg
675 680 685

Ala Trp Arg Thr Phe Val Leu Arg Val Arg Ala Gln Asp Pro Pro Pro
690 695 700

Glu Leu Tyr Phe Val Lys Val Asp Val Thr Gly Ala Tyr Asp Thr Ile
705 710 715 720

Pro Gln Asp Arg Leu Thr Glu Val Ile Ala Ser Ile Ile Lys Pro Gln
725 730 735

Asn Thr Tyr Cys Val Arg Arg Tyr Ala Val Val Gln Lys Ala Ala His
740 745 750

Gly His Val Arg Lys Ala Phe Lys Ser His Val Ser Thr Leu Thr Asp
755 760 765

Leu Gln Pro Tyr Met Arg Gln Phe Val Ala His Leu Gln Glu Thr Ser
770 775 780

Pro Leu Arg Asp Ala Val Val Ile Glu Gln Ser Ser Ser Leu Asn Glu
785 790 795 800

Ala Ser Ser Gly Leu Phe Asp Val Phe Leu Arg Phe Met Cys His His
805 810 815

Ala Val Arg Ile Arg Gly Lys Ser Tyr Val Gln Cys Gln Gly Ile Pro
820 825 830

Gln Gly Ser Ile Leu Ser Thr Leu Leu Cys Ser Leu Cys Tyr Gly Asp
835 840 845

Met Glu Asn Lys Leu Phe Ala Gly Ile Arg Arg Asp Gly Leu Leu Leu
850 855 860

Arg Leu Val Asp Asp Phe Leu Leu Val Thr Pro His Leu Thr His Ala
865 870 875 880

Lys Thr Phe Leu Arg Thr Leu Val Arg Gly Val Pro Glu Tyr Gly Cys
885 890 895

Val Val Asn Leu Arg Lys Thr Val Val Asn Phe Pro Val Glu Asp Glu
900 905 910

Ala Leu Gly Gly Thr Ala Phe Val Gln Met Pro Ala His Gly Leu Phe
915 920 925

Pro Trp Cys Gly Leu Leu Leu Asp Thr Arg Thr Leu Glu Val Gln Ser
930 935 940

Asp Tyr Ser Ser Tyr Ala Arg Thr Ser Ile Arg Ala Ser Leu Thr Phe
945 950 955 960

Asn Arg Gly Phe Lys Ala Gly Arg Asn Met Arg Arg Lys Leu Phe Gly
965 970 975

Val Leu Arg Leu Lys Cys His Ser Leu Phe Leu Asp Leu Gln Val Asn
980 985 990

Ser Leu Gln Thr Val Cys Thr Asn Ile Tyr Lys Ile Leu Leu Gln
995 1000 1005

Ala Tyr Arg Phe His Ala Cys Val Leu Gln Leu Pro Phe His Gln Gln
1010 1015 1020

Val Trp Lys Asn Pro Thr Phe Phe Leu Arg Val Ile Ser Asp Thr Ala
1025 1030 1035 1040

Ser Leu Cys Tyr Ser Ile Leu Lys Ala Lys Asn Ala Gly Met Ser Leu
1045 1050 1055

Gly Ala Lys Gly Ala Ala Gly Pro Leu Pro Ser Glu Ala Val Gln Trp
1060 1065 1070

Leu Cys His Gln Ala Phe Leu Leu Lys Leu Thr Arg His Arg Val Thr
1075 1080 1085

Tyr Val Pro Leu Leu Gly Ser Leu Arg Thr Ala Gln Thr Gln Leu Ser
1090 1095 1100

Arg Lys Leu Pro Gly Thr Thr Leu Thr Ala Leu Glu Ala Ala Ala Asn
1105 1110 1115 1120

Pro Ala Leu Pro Ser Asp Phe Lys Thr Ile Leu Asp
1125 1130

<210> 3
<211> 6
<212> PRT
<213> Homo sapiens

<220>
<221> PEPTIDE
<222> (1)..(6)
<223> amino acid positions 560-565 from hTRT

<400> 3
Phe Phe Tyr Val Thr Glu
1 5

<210> 4
<211> 14
<212> PRT
<213> Homo sapiens

<220>
<221> PEPTIDE
<222> (1)..(14)
<223> amino acid positions 405-418 from hTRT

<400> 4
Tyr Gly Val Leu Leu Lys Thr His Cys Pro Leu Arg Ala Ala
1 5 10

<210> 5
<211> 4
<212> PRT
<213> Homo sapiens

<220>
<221> PEPTIDE
<222> (1)..(4)
<223> amino acid positions 561-564 from hTRT

<400> 5
Phe Tyr Val Thr
1

<210> 6
<211> 25
<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:RT1 oligo

<400> 6

gaaggccgcc cacgggcacg tccgc

25

<210> 7

<211> 32

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:RT2 oligo

<400> 7

cccggccacc ccagccatgg cgcgcgtcc cc

32

<210> 8

<211> 60

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:RT5 oligo

<400> 8

tacggggtgc tcctcaagac gcactgcccg ctgctccgcc agcacagcag cccctggcag 60

<210> 9

<211> 60

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:RT10 oligo

<400> 9

tactccatcc tgaaagccaa gaacgcaggg ctgtgccacc aagcattcct gctcaagctg 60

<210> 10

<211> 60

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:RT11 oligo

<400> 10

ctgtgccacc aagcattcct gctcaagctg gccgcagcca acccggcact gccctcagac 60

<210> 11

<211> 60

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:RT3A oligo

<400> 11

actcaggccc ggccccgcc acacgctagc gagaccaagc acttcctcta ctcctcaggc 60

<210> 12
<211> 60
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:RT4A oligo

<400> 12
actcaggccc ggccccgcc acacgctagc gtggtgtcac ctgccagacc cgccgaagaa 60

<210> 13
<211> 69
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:RT6A oligo

<400> 13
atccccaagc ctgacgggct gcggccgatt gttaacatgc tgttcagcgt gctcaactac 60
gagcgggcg 69

<210> 14
<211> 63
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:RT8A oligo

<400> 14
acgtactgcg tgcgtcggtg tgccgtggtc acagatctcc agccgtacat gcgacagtgc 60
gtg 63

<210> 15
<211> 60
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:RT3A/5 oligo

<400> 15
actcaggccc ggccccgcc acacgctagc ctgctccgcc agcacagcag cccctggcag 60

<210> 16
<211> 63
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:LM121-WG oligo

<400> 16
gttcagatgc cgccccacgg cctattccct ctagataccc ggaccctgga ggtgcagagc 60
gac 63

<210> 17

<211> 50
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:LM122-Nuc oligo

<400> 17
ccctgggcct gccagcccg ggtgccggcg ctgccctga gccggagcgg 50

<210> 18
<211> 60
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:RT3 oligo

<400> 18
gctagtggac cccgaaggcg tctgggatgc gagaccaagc acttcctcta ctctcaggc 60

<210> 19
<211> 60
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:RT4 oligo

<400> 19
gctagtggac cccgaaggcg tctgggatgc gtggtgtcac ctgccagacc cgccgaagaa 60

<210> 20
<211> 60
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:RT6 oligo

<400> 20
gacgggctgc ggccgattgt gaacatggac ctgttcagcg tgctcaacta cgagcgggcg 60

<210> 21
<211> 60
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:RT8 oligo

<400> 21
acgtactgcg tgcgtcggtg tgccgtggtc accttgacag acctccagcc gtacatgcga 60